

Wu-Shang Wang,^{a*} Min Gao,^b
Xiangji Chen^c and Boli Liu^c^aNorthwest Institute of Nuclear Technology, Xi'an, ShannXi 710024, People's Republic of China, ^bDepartment of Applied Chemistry, Faculty of Science, Xi'an Jiaotong University, Xi'an, ShannXi 710049, People's Republic of China, and ^cCollege of Chemistry, Beijing Normal University, Beijing 100875, People's Republic of ChinaCorrespondence e-mail:
nintwsw@yahoo.com.cn

Key indicators

Single-crystal X-ray study
 $T = 296\text{ K}$
Mean $\sigma(\text{C}-\text{C}) = 0.006\text{ \AA}$
 R factor = 0.030
 wR factor = 0.072
Data-to-parameter ratio = 14.3For details of how these key indicators were automatically derived from the article, see <http://journals.iucr.org/e>.


2-(4-Amino-3-iodophenyl)-1,3-benzothiazole

The title molecule, $\text{C}_{13}\text{H}_9\text{IN}_2\text{S}$, is composed of two planar units, namely a substituted aminophenyl ring and a benzothiazole ring system. The maximum deviations from the mean planes fitted through the ring atoms are only 0.010 (5) and 0.027 (6) Å for the aminophenyl and benzothiazole, respectively. In the solid state, the I atom lies on the same side of the molecule as the S atom rather than the N atom of the thiazole ring.

Received 23 September 2006
Accepted 15 November 2006

Comment

Alzheimer's disease (AD), the most common form of dementia in adults, is a neurodegenerative disease characterized by progressive cognitive decline, memory impairment and behavioural changes. Both the incidence and the prevalence of AD increase sharply with age. The accumulation of β -amyloid ($\text{A}\beta$) plaques in the brain may be a key risk factor associated with AD (Hardy *et al.*, 2002; Selkoe, 2000). Therefore, radio-labelled imaging probes for $\text{A}\beta$ plaques may provide valuable information pertinent to the initiation and progression of AD. Of the $\text{A}\beta$ -imaging agents that have been reported previously, radionuclide-labelled 2-(4-aminophenyl)benzothiazole (BTA) analogues are very promising. ^{125}I -labelled 2-(4-aminophenyl)benzothiazole is a potential $\text{A}\beta$ imaging probe (Wang *et al.*, 2003). In order to study the quantitative structure–activity relationship of 2-(4-amino-3-iodophenyl)benzothiazole analogues, the determination of the structure of the title compound, (I), is important.



Iodination reactions may occur at the 3'- or 5'-position of 2-(4'-aminophenyl)benzothiazole. In order to confirm the position of the iodine, the structure of (I) was determined by a single-crystal X-ray diffraction experiment. The molecular structure of (I) is depicted in Fig. 1, and Fig. 2 shows a view of the unit cell contents. The ring atoms involved in both moieties are approximately planar, with a maximum deviation of 0.060 (6) Å (Petricek *et al.*, 2006). In the solid state, the I atom lies on the same side of the molecule as the S atom rather than the N atom of the thiazole ring.

Table 1 lists some important bond distances, while Table 2 gives details of the hydrogen-bond interactions.

Experimental

The synthesis of (I) is shown in the scheme. The intermediate, 2-(4-aminophenyl)benzothiazole, was synthesized as described in the literature (Mathis *et al.*, 2002) and (I) was obtained as described by Shi *et al.* (1996). Suitable crystals were obtained by evaporation of an ethanol solution at room temperature for 7 d (m.p. 422–423 K).

Crystal data

$C_{13}H_9IN_2S$	$Z = 4$
$M_r = 352.18$	$D_x = 1.857 \text{ Mg m}^{-3}$
Monoclinic, $P2_1/c$	Mo $K\alpha$ radiation
$a = 7.8023 (3) \text{ \AA}$	$\mu = 2.69 \text{ mm}^{-1}$
$b = 8.7783 (4) \text{ \AA}$	$T = 296 (2) \text{ K}$
$c = 18.5532 (10) \text{ \AA}$	Prism, colourless
$\beta = 97.446 (4)^\circ$	$0.30 \times 0.13 \times 0.09 \text{ mm}$
$V = 1260.01 (10) \text{ \AA}^3$	

Data collection

Bruker SMART APEX-II CCD diffractometer	4249 measured reflections
φ and ω scans	2199 independent reflections
Absorption correction: multi-scan (SADABS; Bruker, 2000)	1552 reflections with $I > 2\sigma(I)$
$T_{\min} = 0.658$, $T_{\max} = 0.785$	$R_{\text{int}} = 0.029$
	$\theta_{\text{max}} = 25.1^\circ$

Refinement

Refinement on F^2	H-atom parameters constrained
$R[F^2 > 2\sigma(F^2)] = 0.030$	$w = 1/[\sigma^2(F_o^2) + (0.0357P)^2]$
$wR(F^2) = 0.072$	where $P = (F_o^2 + 2F_c^2)/3$
$S = 0.97$	$(\Delta/\sigma)_{\text{max}} = 0.001$
2199 reflections	$\Delta\rho_{\text{max}} = 0.41 \text{ e \AA}^{-3}$
154 parameters	$\Delta\rho_{\text{min}} = -0.37 \text{ e \AA}^{-3}$

Table 1

Selected bond lengths (\AA).

I1–C2	2.100 (4)	S1–C7	1.752 (4)
S1–C8	1.735 (5)		

Table 2

Hydrogen-bond geometry (\AA , $^\circ$).

$D-H\cdots A$	$D-H$	$H\cdots A$	$D\cdots A$	$D-H\cdots A$
$N2-H2B\cdots I1$	0.86	2.79	3.248 (4)	115
$N2-H2A\cdots N1^i$	0.86	2.26	3.097 (5)	166
$C3-H3\cdots S1$	0.93	2.70	3.116 (4)	108

Symmetry code: (i) $-x + 2, y - \frac{1}{2}, -z + \frac{1}{2}$.

All H atoms were discernible in a difference Fourier map. They were placed in calculated positions ($N-H = 0.86$, $C-H = 0.93$) and refined using a riding model, $U_{\text{iso}}(\text{H}) = 1.2U_{\text{eq}}(\text{N,C})$.

Data collection: SMART (Bruker, 2001); cell refinement: SMART; data reduction: SAINT (Bruker, 2001); program(s) used to solve structure: SHELXS97 (Sheldrick, 1997); program(s) used to refine structure: SHELXL97 (Sheldrick, 1997); molecular graphics:




Figure 1

The molecular structure of (I), showing displacement ellipsoids drawn at the 50% probability level.




Figure 2

A packing diagram of (I). Dashed lines indicate hydrogen bonds.

SHELXTL (Bruker, 2001); software used to prepare material for publication: SHELXTL.

References

- Bruker (2000). *SADABS*. Version 2.10. Bruker AXS Inc., Madison, Wisconsin, USA.
- Bruker (2001). *SMART* (Version 5.625), *SAINT* (Version 6.36) and *SHELXTL* (Version 6.12). Bruker AXS Inc., Madison, Wisconsin, USA.
- Hardy, J. & Selkoe, D. J. (2002). *Science*, **295**, 353–356.
- Mathis, C. A., Bacskaï, B. J., Kajdasz, S. T., McLellan, M. E., Frosch, M. P., Hyman, B. T., Holt, D. P., Wang, Y., Huang, G. F., Debnath, M. L. & Klunk, W. E. (2002). *Med. Chem. Lett.* **12**, 295–298.
- Petricek, V., Dusek, M. & Palatinus, L. (2006). *JANA2000*. Institute of Physics, Czech Academy of Sciences, Praha, Czech Republic.
- Selkoe, D. J. (2000). *Nat. Biotechnol.* **18**, 823–824.
- Sheldrick, G. M. (1997). *SHELXS97* and *SHELXL97*. University of Göttingen, Germany.
- Shi, D. F., Bradshaw, T. D., Wrigley, S., McCall, C. J., Lelieveld, P., Fichtner, I. & Stevens, M. F. (1996). *J. Med. Chem.* **39**, 3375–3384.
- Wang, Y., Mathis, C. A., Huang, G. F., Debnath, M. L., Holt, D. P., Shao, L. & Klunk, W. E. (2003). *J. Mol. Neurosci.* **20**, 255–260.